(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Very good quality Greens All over The Planet - 2The Tradition of Stone: A Gander at Notable Structures Through the Ages
- 3Activists guilty over Palestine protest breach
- 4Artemis II astronauts say they're "ready to go" for moon launch
- 57 Powerful Techniques to Boost Efficiency with Your Cell Phone: A Far reaching Guide
- Burger King launches 'SpongeBob' menu ahead of film's release. A look at the Bikini Bottom-inspired meal, plus what taste testers are saying.
- Best Amusement Park in Europe: Where Do You Very much want to Visit?
- From Dread to Certainty: Individual Accounts of Strengthening
- Record-breaking 'space laser' erupts from merging galaxies 8 billion light-years away
- People with depression can treat themselves at home with new device
- UNICEF: More than 100 children killed in Gaza since ceasefire
- Mountain Trekking on a Tight spending plan: Tracking down the Right Bicycle
- 6 Famous kind of practice on the planet
- Exploring the Main Year of Life as a parent: Individual Encounters
